Results 51 to 60 of about 26,025 (223)

Targeting CDK6 and BCL2 Exploits the MYB Addiction of Ph+ Acute Lymphoblastic Leukemia [PDF]

, 2018
Philadelphia chromosome–positive acute lymphoblastic leukemia (Phþ ALL) is currently treated with BCR-ABL1 tyrosine kinase inhibitors (TKI) in combination with chemotherapy. However, most patients develop resistance to TKI through BCR-ABL1–dependent and –
Addya, Sankar, Calabretta, Bruno, De Dominici, Marco, Ferrari, Anna, Fortina, Paolo, Iacobucci, Ilaria, Mariani, Samanta A., Martinelli, Giovanni, Peterson, Luke F., Porazzi, Patrizia, Rambaldi, Alessandro, Soliera, Angela Rachele, Spinelli, Orietta   +12 more
core   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu, Lingyao Zeng, Xulin Gan, Yilin Zhou, Han Shen, Dan Wu, Xin Shou, Minmin Jiang, Liyun Shi   +8 more
wiley   +1 more source

Biological aspects of mTOR in leukemia [PDF]

, 2018
The mammalian target of rapamycin (mTOR) is a central processor of intra-and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival.
Bianchi, Mp, Gianfelici, V, Mirabilii, S, Piedimonte, M, Ricciardi, Mr, Tafuri, A.   +5 more
core   +1 more source

Toward Predictable Nanomedicine: Current Forecasting Frameworks for Nanoparticle–Biology Interactions

Advanced Intelligent Discovery, EarlyView.
Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova, Michael Nicholls, Nicola Russo, Gueorgui Mihaylov, Konstantin Nikolic   +4 more
wiley   +1 more source

Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients

Clinical and Translational Science
Venetoclax, a small molecule inhibitor of BCL‐2, has demonstrated efficacy in treating acute leukemias and has been recommended as one of the first‐line anti‐leukemia therapies.
Yuan Jian, Feifei Han, Ying Zhu, Chuanying Geng, Yanru Zhang, Yin Wu, Yun Leng, Wenming Chen, Zhuoling An, Hong‐Hu Zhu   +9 more
doaj   +1 more source

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis

Clinical and Translational Science, 2019
Venetoclax is an approved drug for the treatment of some hematological malignancies. Venetoclax can cause reduction in B‐lymphocyte counts as an on‐target effect.
Nimita Dave, Sathej Gopalakrishnan, Sven Mensing, Ahmed Hamed Salem   +3 more
doaj   +1 more source

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

Haematologica, 2023
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary.
Jonathan A. Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T. Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O’Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Katie Zhou, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea   +22 more
doaj   +1 more source

Real‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

American Journal of Hematology, EarlyView.
ABSTRACT In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary ...
Gaspar Aspas Requena, Rebeca Rodríguez‐Veiga, Cristina Gil, Carmen Botella, Eliana Aguiar, Fernanda Trigo, Mercedes Colorado, Teresa del Bernal del Castillo, Eva Barragan, Mar Tormo, Eduardo Rodríguez Arbolí, Josefina Serrano López, Raimundo García Boyero, Tamara Castaño, Pilar Herrera Puente, Mónica A. Romero Riquelme, María J. Sayas Lloris, Lorenzo Algarra‐Algarra, Carlos Rodriguez‐Medina, Claudia L. Sossa Melo, Jorge Labrador Gomez, Susana Vives, Olga Salamero, María Luz Amigo, Marta Valero Nuñez, Christine Rojas, Francisca Bass, María García‐Fortes, Belén Vidriales Vicente, Marta Polo, Celina Benavente, María D. Madrigal, Marcela Espinoza, Manuel Pérez‐Encinas, María L. Amador Barciela, Guiomar Bautista, Antonio Solana‐Altabella, Isabel Cano‐Ferri, Rafael Colmenares, Patricia García‐Ramírez, Francisco Ibáñez Alis, Manuel Barrios García, Gabriela Rodríguez‐Macías, Miguel López, Ana Yurena Oliva Hernández, Carlos Javier Cerveró, David Martínez‐Cuadrón, Pedro Chorão, Juan M. Bergua Burgues, Pau Montesinos   +49 more
wiley   +1 more source

Exportin 1 Inhibitor Combined With Venetoclax Induces Apoptosis in Myelodysplastic Syndrome by Mitochondria‐Induced Apoptosis Pathway

Journal of Clinical Laboratory Analysis, EarlyView.
Inhibition of XPO1 is a promising modality in the treatment of MDS, especially when combined with Venetoclax, which activates mitochondria‐mediated apoptosis and could be a potential target for MDS therapy. ABSTRACT Background Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies that pose a serious health threat.
Xiaohan Liu, Lei Huang, Junzhu Wang, Yixuan Guo, Hongli Shen, Xianghong Zhao, Lanzhu Yue, Zhaoyun Liu, Rong Fu   +8 more
wiley   +1 more source

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition

Biomolecules, 2020
Anti-apoptotic Bcl-2-family members are frequently dysregulated in both blood and solid cancers, contributing to their survival despite ongoing oncogenic stress.
Martijn Kerkhofs, Tamara Vervloessem, Kinga B. Stopa, Victoria M. Smith, Meike Vogler, Geert Bultynck   +5 more
doaj   +1 more source